– May 12, 2025 announcement of positive interim data from ongoing Phase 1 study of CX-2051 (EpCAM Antibody Drug Conjugate) in patients with advanced colorectal cancer (CRC) – – CX-2051 Phase 1 dose expansions on track for data update in Q1 2026. Phase 2 study initiation in CRC anticipated 1H 2026 – – Combination dose escalation initiated of CX-801 masked interferon alpha-2b with KEYTRUDA® (pembrolizumab) in patients with advanced melanoma – – Completed $100 million underwritten offering of commoRead More
CytomX Therapeutics Announces Second Quarter 2025 Financial Results and Provides Business Update
